Information Provided By:
Fly News Breaks for August 1, 2019
AMD, MXIM, AMAG, SAVA, CRSP
Aug 1, 2019 | 10:13 EDT
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. AMD (AMD) and Maxim Integrated (MXIM) initiated with a Hold at Benchmark. 2. Amag Pharmaceuticals (AMAG) and Cassava Sciences (SAVA) initiated with a Buy at H.C. Wainwright. 3. Crispr Therapeutics (CRSP) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
News For AMD;MXIM;AMAG;SAVA;CRSP From the Last 2 Days
SAVA
Sep 16, 2019 | 08:33 EDT
Cassava Sciences reported initiation of a Phase 2b study of its lead drug candidate, PTI-125, in Alzheimer's patients. PTI-125 is a small molecule that targets the massive neuroinflammation and neurodegeneration observed in the Alzheimer's brain. In conjunction with the initiation of this Phase 2b study, Cassava Sciences also reported dosing of the first two patients for this study, both of which were uneventful. This Phase 2b study is supported by a research grant award from the National Institutes of Health. Initiation of the Phase 2b study follows results reported from a Phase 2a study, demonstrating 100% responder rate and statistically significant decreases in key biomarkers of Alzheimer's pathology, neuroinflammation and neurodegeneration.